Clinical Trial Detail

NCT ID NCT02543879
Title Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Forma Therapeutics, Inc.
Indications

acute myeloid leukemia

myelodysplastic syndrome

non-Hodgkin lymphoma

B-cell lymphoma

primary mediastinal B-cell lymphoma

acute leukemia

diffuse large B-cell lymphoma

Therapies

FT-1101

Azacitidine + FT-1101

Age Groups: adult senior

Additional content available in CKB BOOST